Rigrodsky & Long, P.A.:
- Do you own shares of Innotrac Corporation (NASDAQ CM: INOC )?
- Did you purchase any of your shares prior to November 14, 2013?
- Do you think the proposed buyout price is too low?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Innotrac Corporation (“Innotrac” or the “Company”) (NASDAQ CM: INOC) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by an affiliate of Sterling Partners (“Sterling”) in a transaction valued at approximately $108 million.
Click here to learn more: http://www.rigrodskylong.com/investigations/innotrac-corporation-inoc.
Under the terms of the agreement, public shareholders of Innotrac will receive $8.20 per share in cash for each share of Innotrac they own.The investigation concerns whether Innotrac’s board of directors failed to adequately shop the Company and obtain the best possible value for Innotrac’s shareholders before entering into an agreement with Sterling. If you own the common stock of Innotrac and purchased your shares before November 14, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530, by telephone at (888) 969-4242; by e-mail to email@example.com, or at: http://www.rigrodskylong.com/investigations/innotrac-corporation-inoc. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.